Last week, Lizzy Liu and Mackenzie Bourke presented in an organised session at the AHES Conference in Canberra on the value of population-wide genomic risk assessment for cancer screening, alongside A/Prof Julia Steinberg from the Daffodil Centre.

(1/4) INVITATION: Applying #MendelianRandomization in #HealthEconomics - Bridging #Genomics & #CostEffectiveness 🗓️ Tues 16 Sept ⏰8-9 AM UTC / 9-10 AM BST / 6-7 PM AEST 📍Online, download the calendar invite here: healtheconomics.org/event/applyi...

(1/4) INVITATION: Webinar exploring distributional cost-effectiveness analysis (#DCEA) for advancing #healthequity 🗓️ Date & time: 6-7pm Wed 8 Oct EDT / 10-11pm Wed 8 Oct UTC / 9-10am Thurs 9 Oct AEDT 📍 Online, download the calendar invitation here: healtheconomics.org/event/advanc...

📢 New publication in The European Journal of Health Economics! The paper assesses the psychometric performance CHU9D proxy version compared with the PedsQL in Australian children aged 0–7 years with congenital colorectal conditions. Read our findings: link.springer.com/article/10.1...

Recently our team conducted two #DCEs as part of the BabyScreen+ program to elicit the Australian public’s preferences, values, and priorities for genomic newborn screening (gNBS) and its implementation. Read more here: sciencedirect.com/science/arti...

Excited to welcome Thuy Dung (“Dzung”) Nguyen as our new Research Assistant in the Economics of Genomics and Precision Medicine Unit! Dzung will be contributing to a project evaluating the cost-effectiveness of genomic testing for children/adults with suspected kidney disease.

A few weeks ago, @iliasgoranitis.bsky.social presented at the Pan American Health Organisation webinar series. The webinar explored the challenges and opportunities of incorporating genomic innovations into health systems. youtube.com/watch?v=cPQr...

🔬 Excited to share our latest work: "The Cost Effectiveness of Genomic Medicine in Cancer Control", in collaboration with Cancer Australia and @who.int.

Preferences like testing uptake, treatment adherence, and trust in the healthcare system are key to evaluating genomic medicine. Ignoring them can bias cost-effectiveness and policy relevance. 🔎 Read the paper our team supported: rdcu.be/eaJBy

How has publicly funded genetic and genomic tests been used in Australia? Read our recent study on test utilisation and MBS funding here: www.nature.com/articles/s41...

Our team recently developed the Genomic Utility Valuation scale (#GUVscale), which systematically collects and weights key genomic outcomes to inform research, healthcare decision-making, and reimbursement priorities.

Cancer Australia recently launched the National Framework for Genomics in Cancer Control, a major step toward integrating genomics into routine cancer care for all Australians. Read the Framework: canceraustralia.gov.au/key-initiati...

Our recent micro-costing paper found that proteomics offers a more cost-effective solution with broader applications compared to respiratory chain enzymology for mitochondrial disorders in Australia. Read more of our findings here: ojrd.biomedcentral.com/articles/10....

Exciting research in #genomic_newborn_screening (gNBS)! Ilias and Riccarda contributed to this paper exploring public perspectives on which conditions should be included in #gNBS. Read more here: link.springer.com/article/10.1...

Our team, in collaboration with @ausgenomics.bsky.social, identified priority indicators for assessing the value of #genomic_testing in #rare_diseases, an important step toward standardising evidence generation. Read more here: pubmed.ncbi.nlm.nih.gov/38459833/

An interesting paper from our team on #additional_findings in #genomic_sequencing. We report results from a #DCE exploring parental preferences for the process of returning additional findings and the value placed on this analysis for children with rare conditions. Read more here: rdcu.be/dyDkq